Enhanced in vivo airway gene transfer via transient modification of host barrier properties with a surface-active agent

被引:66
作者
Parsons, DW [1 ]
Grubb, BR [1 ]
Johnson, LG [1 ]
Boucher, RC [1 ]
机构
[1] Univ N Carolina, Dept Med, Cyst Fibrosis Ctr, Chapel Hill, NC 27599 USA
关键词
D O I
10.1089/hum.1998.9.18-2661
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Effective adenoviral gene therapy requires efficient viral vector entry into epithelial cells. Injured airway epithelia display enhanced gene transfer, reflecting in part increased vector access to protected cell populations and/or protected basolateral membranes. We tested whether adenoviral gene transfer is enhanced by modification of the epithelial barrier in mouse nasal airways with a nonionic detergent (polidocanol, PDOC). In C57BL/6 mice, 1.6 x 10(9) PFU of Ad5CMV LacZ (AdLacZ) instilled into the right nostril produced negligible gene transfer to the nasal epithelium 2 days after dosing, but significant, dose-dependent increases in gene transfer were achieved by pretreatment with PDOC. Permeation of the electron-dense tracer lanthanum into the intercellular junctions of PDOC (0.1%)-treated murine nasal epithelium, but not into intercellular junctions of vehicle controls, is consistent with PDOC-mediated increases in tight junctional permeability. In CF(-/-) mice, significant gene expression was not detectable after exposure to Ad5CBCFTR alone (1.4 x 10(9) PFU in 20 mu l; AdCFTR), but PDOC pretreatment prior to AdCFTR instillation produced functional expression of CFTR (measured as Delta PD) 5 days after instillation. Because the development and testing of lung gene therapy will principally occur in children and adults with airway disease, AdLacZ gene transfer with and without PDOC pretreatment was examined in infected nasal airways. Gene expression was significantly reduced in infected as compared with uninfected airways. We conclude that the use of adjuvant surface-active and/or membrane-perturbing agents, synthetic or naturally derived, may provide a novel approach to enhancing the efficiency of adenoviral gene transfer.
引用
收藏
页码:2661 / 2672
页数:12
相关论文
共 46 条
[1]   NASAL ABSORPTION OF INTERFERON - ENHANCEMENT BY SURFACTANT AGENTS [J].
BAGLIONI, C ;
PHIPPS, RJ .
JOURNAL OF INTERFERON RESEARCH, 1990, 10 (05) :497-504
[2]   Current status of CF gene therapy [J].
Boucher, RC .
TRENDS IN GENETICS, 1996, 12 (03) :81-84
[3]   TRANSPORT OF INSULIN ACROSS RABBIT NASAL-MUCOSA INVITRO INDUCED BY DIDECANOYL-L-ALPHA-PHOSPHATIDYLCHOLINE [J].
CARSTENS, S ;
DANIELSEN, G ;
GULDHAMMER, B ;
FREDERIKSEN, O .
DIABETES, 1993, 42 (07) :1032-1040
[4]   DEFECTIVE EPITHELIAL CHLORIDE TRANSPORT IN A GENE-TARGETED MOUSE MODEL OF CYSTIC-FIBROSIS [J].
CLARKE, LL ;
GRUBB, BR ;
GABRIEL, SE ;
SMITHIES, O ;
KOLLER, BH ;
BOUCHER, RC .
SCIENCE, 1992, 257 (5073) :1125-1128
[5]   A PHASE-1 STUDY, IN CYSTIC-FIBROSIS PATIENTS, OF THE SAFETY, TOXICITY, AND BIOLOGICAL EFFICACY OF A SINGLE ADMINISTRATION OF A REPLICATION DEFICIENT, RECOMBINANT ADENOVIRUS CARRYING THE CDNA OF THE NORMAL CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE IN THE LUNG [J].
CRYSTAL, RG ;
JAFFE, A ;
BRODY, S ;
MASTRANGELI, A ;
MCELVANEY, NG ;
ROSENFELD, M ;
CHU, CS ;
DANEL, C ;
HAY, J ;
EISSA, T .
HUMAN GENE THERAPY, 1995, 6 (05) :643-666
[6]   ADMINISTRATION OF AN ADENOVIRUS CONTAINING THE HUMAN CFTR CDNA TO THE RESPIRATORY-TRACT OF INDIVIDUALS WITH CYSTIC-FIBROSIS [J].
CRYSTAL, RG ;
MCELVANEY, NG ;
ROSENFELD, MA ;
CHU, CS ;
MASTRANGELI, A ;
HAY, JG ;
BRODY, SL ;
JAFFE, HA ;
EISSA, NT ;
DANEL, C .
NATURE GENETICS, 1994, 8 (01) :42-51
[7]   ABSORPTION OF RECOMBINANT METHIONYL-HUMAN GROWTH-HORMONE (MET-HGH) FROM RAT NASAL-MUCOSA [J].
DAUGHERTY, AL ;
LIGGITT, HD ;
MCCABE, JG ;
MOORE, JA ;
PATTON, JS .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1988, 45 (03) :197-206
[8]   Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector [J].
Dong, JY ;
Wang, DH ;
VanGinkel, FW ;
Pascual, DW ;
Frizzell, RA .
HUMAN GENE THERAPY, 1996, 7 (03) :319-331
[9]  
Dorin JR, 1996, GENE THER, V3, P797
[10]   CORRECTION OF THE CYSTIC-FIBROSIS DEFECT INVITRO BY RETROVIRUS-MEDIATED GENE-TRANSFER [J].
DRUMM, ML ;
POPE, HA ;
CLIFF, WH ;
ROMMENS, JM ;
MARVIN, SA ;
TSUI, LC ;
COLLINS, FS ;
FRIZZELL, RA ;
WILSON, JM .
CELL, 1990, 62 (06) :1227-1233